Targeting ANGPTL3 to lower lipids

Steve Nichols outlines the first human CRISPR trial reducing ANG-PTL3, cutting LDL and triglycerides substantially.

Play episode from 16:29

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!